Oestrogel

Oestrogel is a transdermal oestradiol gel supplied in a pump-action bottle, prescribed for the relief of menopausal symptoms and the prevention of postmenopausal osteoporosis. Each full pump actuation delivers 2.5g of gel containing 1.5mg of oestradiol. The prescribed dose ranges from one to three measured applications daily, applied by hand to the skin of the upper arms or inner thighs, allowing serum oestradiol levels to be titrated to the individual woman's symptom response under prescriber guidance.

Oestrogel is an oestrogen-only preparation. Women who have not had a hysterectomy require a separately prescribed progestogen to protect the womb lining from the stimulating effects of unopposed oestrogen. Women who have had a hysterectomy may use Oestrogel as their sole HRT. The gel format delivers oestradiol transdermally, bypassing first-pass hepatic metabolism and the venous thromboembolism risk associated with oral oestrogen. Oestrogel is manufactured by Besins Healthcare UK Ltd and is classified as a Prescription Only Medicine.

Oestrogel is an aqueous, alcohol-free gel containing oestradiol 0.06% w/w. Each 80g bottle delivers 64 measured pump actuations, each dispensing exactly 2.5g of gel. The gel is water-based, non-greasy, and dries within a few minutes of application. The alcohol-free formulation distinguishes it from the Lenzetto transdermal spray, which uses an alcohol carrier, and from some other topical oestradiol products. The absence of alcohol reduces the risk of skin dryness and irritation at the application site.

Each 2.5g actuation contains 1.5mg of oestradiol. At the standard starting dose of two applications daily, each pump delivers 1.5mg and the total daily oestradiol dose is 3mg. Because the gel is applied to a larger skin surface area than a patch or spray, the absorption is spread across more capillary beds, which supports a relatively even serum oestradiol profile throughout the day.

Oestrogel contains no progestogen. It is suitable as sole HRT for women without a uterus, and must always be used alongside a separately prescribed progestogen in women who retain their womb, regardless of menopausal status.

Transdermal absorption and the hepatic bypass advantage

After Oestrogel is spread across the skin surface, oestradiol diffuses through the stratum corneum, the outermost skin layer, and into the dermis below. From the dermal capillary network it enters venous circulation and travels systemically without passing through the liver first. This avoidance of first-pass hepatic metabolism is the defining pharmacological advantage shared by all transdermal oestrogen preparations, including patches, sprays, and gels.

Oral oestrogen, by contrast, is absorbed through the gut and processed by the liver before reaching systemic circulation. This hepatic first-pass stimulates production of clotting factors, C-reactive protein, and sex hormone binding globulin, contributing to the higher venous thromboembolism risk associated with oral oestrogen compared with the transdermal route. Observational evidence from Vinogradova et al. (BMJ, 2019) consistently supports the lower thromboembolism risk of transdermal preparations, which is clinically relevant for women with personal or family cardiovascular risk factors.

How gel application distributes absorption

The larger surface area of gel application, typically the inner surface of both upper arms or the inner thighs, means that oestradiol absorption occurs across a more distributed capillary network than with a small patch or spray. This results in a smoother pharmacokinetic profile without the localised peak absorption that can occur at a smaller patch site. The rate of absorption depends on the consistency of the application area, skin temperature, and whether any occlusive products such as moisturisers or sunscreen are applied over the gel before it has dried.

Oestradiol at its receptor targets

Once in systemic circulation, oestradiol from Oestrogel binds to oestrogen receptors throughout the body. In the hypothalamus, it modulates the thermoregulatory control mechanism that becomes dysregulated at the menopause, reducing vasomotor symptoms including hot flushes and night sweats. In the urogenital tissues, it restores cellular integrity to the vaginal and urethral epithelium, improving lubrication and reducing the symptoms of genitourinary syndrome. In bone, it inhibits osteoclast-driven resorption, helping to preserve bone mineral density and reduce the risk of osteoporotic fracture.

Preparing the bottle for first use

Before using Oestrogel for the first time, prime the pump by pressing it down two or three times, directing the dispensed gel onto a tissue and discarding it. This primes the pump mechanism and ensures that the first therapeutic actuation delivers an accurate full dose. The pump does not need to be reprimed after this initial preparation.

Applying the gel

Dispense the prescribed number of pump actuations directly onto the palm or the application site. Spread the gel evenly over a large surface area using the flat of your hand. The recommended sites are the upper arms from shoulder to elbow, or the inner thighs. Applying to a larger surface area improves absorption consistency and reduces the risk of localised skin reaction at any single site.

Rub the gel in gently until it has been absorbed. Do not rub vigorously, as this can cause friction-related irritation. Allow the gel to dry completely before dressing. This takes approximately two to three minutes under normal conditions. Do not apply Oestrogel to the breasts, face, or genitals. Avoid applying to broken, irritated, or sunburned skin.

Skin products and the two-hour rule

Do not apply sunscreen, moisturiser, body lotion, or any other topical preparation to the treated area for at least two hours after applying Oestrogel. Applying these products before the gel has fully absorbed into the skin can alter the rate and completeness of oestradiol uptake. This two-hour interval applies to both the same skin area and to an immediately adjacent area where product may spread.

Protecting others from oestradiol transfer

Oestradiol can transfer from the treated skin to another person through direct skin contact while the gel is still wet or in the two-hour absorption window. Children, men, and other women should not touch the application area until the gel has dried and at least two hours have passed. Unintentional oestrogen exposure can affect hormonal development in children and cause oestrogenic side effects in men. Cover the treated area with clothing if close physical contact with others is anticipated during this period.

Timing and consistency

Apply Oestrogel at the same time each day, ideally at a time when the two-hour skin care avoidance window is easiest to observe. A morning routine, applied before or after showering but allowing the skin to dry first, suits many women. Consistent daily timing supports stable serum oestradiol levels and reduces the likelihood of breakthrough vasomotor symptoms between doses.

Missed dose

If you forget to apply Oestrogel and remember on the same day, apply the dose as soon as possible. If you only remember the following day, skip the missed application and resume your normal schedule. Do not apply a double dose. Occasional missed applications may result in a brief return of hot flushes or other vasomotor symptoms, which resolve when regular dosing resumes.

Oestrogel 0.06% gel: 1.5mg oestradiol per pump actuation

Every pump actuation of Oestrogel delivers exactly 2.5g of 0.06% oestradiol gel, containing 1.5mg of oestradiol. The dose is adjusted by varying the number of daily applications within the prescribed range of one to three actuations. Because the oestradiol content per actuation is fixed, the daily dose is predictable: one actuation delivers 1.5mg, two actuations deliver 3mg, and three actuations deliver 4.5mg of oestradiol per day.

One actuation daily: 1.5mg oestradiol

The lowest daily dose available from Oestrogel. This starting level is appropriate for women who are initiating transdermal HRT cautiously, who have been oestrogen-depleted for an extended period, or who have specific risk factors for which minimal initial oestrogenic exposure is clinically preferred. If symptoms are not adequately controlled at 1.5mg after a review period, the prescriber may step up to two actuations.

Two actuations daily: 3mg oestradiol

The most commonly prescribed maintenance dose. Two actuations apply to two separate skin sites, one on each arm or both inner thighs, to spread absorption and avoid over-saturation at a single application area. This dose is within the standard transdermal oestradiol therapeutic range and provides moderate symptom relief for most women. The prescriber will assess response at three months.

Three actuations daily: 4.5mg oestradiol

The maximum licensed daily dose of Oestrogel. It is considered where two actuations have not produced adequate vasomotor symptom control after a proper assessment period, or for women with higher oestrogen requirements such as those with premature ovarian insufficiency. At this dose the gel is applied to three separate skin areas, spreading absorption across both arms and one thigh, for example, to prevent site saturation. The prescriber will assess clinical justification and ongoing benefit at each review.

Adding progestogen for women with a uterus

The prescriber will co-prescribe a progestogen alongside Oestrogel for women who have not had a hysterectomy. The progestogen may be an oral tablet taken cyclically or continuously, a progestogen-releasing intrauterine device, or a separate preparation. The choice depends on the woman's menopausal stage, bleed preference, and individual clinical history. Women with a uterus must not omit the progestogen.

Application site reactions

Because Oestrogel is applied directly to the skin by hand, local reactions at the application area are possible. The alcohol-free formulation reduces the risk of dryness or stinging that can occur with alcohol-based topical preparations, but some women still experience:

• Mild erythema or redness at the treated skin area
• Localised itching or skin sensitivity
• Dry or flaking skin at application sites with repeated daily use

Rotating the application site between both arms and alternating with the inner thighs reduces cumulative irritation. If skin reactions are persistent or spreading, contact your prescriber.

Systemic oestrogenic effects

The following effects are commonly reported during the first weeks of Oestrogel use as serum oestradiol levels stabilise, and generally resolve within the first two to three months:

• Breast tenderness or fullness
• Headache or migraine
• Nausea or mild abdominal discomfort
• Bloating or fluid retention
• Mood change or heightened emotional sensitivity
• Leg cramps

If these persist beyond three months, speak to your prescriber. A dose adjustment or formulation change may be considered if they are significantly affecting daily life.

Serious effects requiring emergency care

Seek immediate emergency medical attention for:

• Sudden chest pain, breathlessness, or coughing blood — possible pulmonary embolism
• Unilateral leg swelling, pain, or warmth — possible deep vein thrombosis
• Sudden severe headache, visual disturbance, facial drooping, or one-sided weakness — possible stroke
• Jaundice or severe right upper abdominal pain
• A new or unexplained breast lump
• Unexplained vaginal bleeding in a postmenopausal woman, or bleeding outside the expected pattern for women using a progestogen cyclically

Long-term risk

Oestrogen-only HRT is associated with a smaller increase in breast cancer risk than combined HRT, based on the Lancet 2019 analysis. For women using Oestrogel with a separately prescribed progestogen, the combined risk profile will depend on the progestogen chosen. Transdermal oestradiol is associated with a lower venous thromboembolism risk than oral oestrogen equivalents, based on observational evidence. Your prescriber will assess the individual benefit-risk balance at each annual review.

Licensed indications

• Relief of symptoms of oestrogen deficiency in menopausal women, including hot flushes, night sweats, vaginal dryness, mood disturbance, and sleep disruption
• Prevention of osteoporosis in postmenopausal women at increased fracture risk where other treatments are not suitable or tolerated

Women particularly suited to the gel format

Oestrogel is a clinically relevant choice for:

• Women who find patch adhesion unreliable or experience skin reactions at adhesive patch sites
• Women who have experienced skin irritation from the alcohol carrier in transdermal sprays
• Women with cardiovascular or thrombotic risk factors for whom the lower venous thromboembolism risk of transdermal oestrogen is clinically important over oral HRT
• Women who benefit from the flexible dose range of one to three actuations, allowing the prescriber to titrate oestradiol exposure more granularly than fixed-dose patches
• Women who have had a hysterectomy and require oestrogen-only therapy without a progestogen

Absolute contraindications

Oestrogel must not be used in women who have, or have had:

• Known, suspected, or previous breast cancer
• Known or suspected oestrogen-sensitive malignancies
• Undiagnosed or unexplained vaginal bleeding
• Active or previous venous thromboembolism or known thrombophilic disorders
• Active or recent arterial thromboembolic disease, including myocardial infarction, angina, or stroke
• Active liver disease or persistently abnormal liver function
• Known hypersensitivity to oestradiol or any gel excipient
• Porphyria

Clinical caution required

Prescribers will exercise additional caution in women with hypertension, uterine fibroids, migraine with aura, gallbladder disease, diabetes, systemic lupus erythematosus, a personal or close family history of breast cancer, or previous endometrial hyperplasia. Women who have not had a hysterectomy must use Oestrogel alongside a prescribed progestogen without exception.

Oestrogel is a Prescription Only Medicine. A clinical consultation is the required first step. A prescription is a possible outcome of that consultation, not a guaranteed one. The prescriber must assess whether the transdermal gel route is appropriate for the individual patient, determine the correct starting dose, and establish whether a concurrent progestogen prescription is required.

At Pharmacy Planet, your consultation will cover your menopausal symptoms and their effect on daily life, your gynaecological and surgical history including whether you have had a hysterectomy, previous HRT use and tolerability including any history of skin reactions to transdermal preparations, current medicines and supplements, and personal and family medical history relevant to HRT safety.

If you have previously used a transdermal patch or spray and have reasons for preferring a gel, sharing this during the consultation helps the prescriber understand your clinical and practical requirements. Specific concerns such as skin reactions at adhesive patch sites, difficulty maintaining patch adhesion, or sensitivity to alcohol-based carriers are all directly relevant to the prescribing decision.

A review appointment is typically scheduled at three months after the initial prescription. This review assesses whether the starting dose is providing adequate symptom control and whether any side effects have emerged. Annual reviews follow, reassessing the dose and formulation appropriateness as circumstances evolve. Because Oestrogel offers three dose steps within a single product, dose adjustments can be made without switching preparations.

Store Oestrogel below 25°C in a dry place, away from direct sunlight and heat sources. Do not freeze the bottle. The gel consistency and pump mechanism can be affected by extreme temperatures, both high and low, which may alter the volume dispensed per actuation or the consistency of the gel applied to the skin.

Keep the bottle upright when not in use, with the cap firmly closed to prevent evaporation of the aqueous gel base. Do not decant Oestrogel into another container, as this removes the accurate pump-measured dosing system and introduces the risk of dose inconsistency.

Keep out of the sight and reach of children and pets. Oestrogel contains pharmacologically active oestradiol in a readily absorbed gel form. Accidental skin exposure in a child represents a genuine hormonal exposure risk. Wash hands thoroughly with soap and water after every application before touching children or food preparation surfaces. Return unused or expired bottles to your community pharmacy for safe disposal. Do not dispose of in household waste.

Choosing the right HRT is a clinical decision, not a one-size-fits-all choice. Delivery route, oestrogen type, progestogen class, and bleed preference all shape which preparation is most appropriate for any individual woman. The table below compares commonly prescribed oestradiol gels and sprays. All are transdermal preparations that bypass the liver. They require a separately prescribed progestogen for women with a uterus. Note differences in application site and formulation: Oestrogel and Sandrena are alcohol-free gels; Lenzetto uses an alcohol-based carrier.

Pharmacy Planet is a GPhC-registered online pharmacy operating under the clinical oversight of a qualified superintendent pharmacist. All prescriptions are issued by registered healthcare professionals applying clinical evidence, current NICE guidance, and the individual patient's complete medical history to each decision.

Prescribing Oestrogel involves more than choosing a transdermal oestrogen. The prescriber must identify the appropriate starting dose within the one-to-three actuation range, determine whether a progestogen co-prescription is needed, assess whether the gel format addresses any specific skin tolerance concerns from previous HRT use, and provide clear guidance on the two-hour skin care window and the contact transfer precautions. Our prescribers bring this clinical and practical knowledge to every Oestrogel consultation. If you would like to find out whether Oestrogel may be appropriate for you, begin a consultation using the link on this page.

1. Oestrogel 0.06% Gel — Summary of Product Characteristics. Besins Healthcare UK Ltd. Available at: https://www.medicines.org.uk/emc. Accessed June 2025.
2. NHS. Hormone replacement therapy (HRT). Available at: https://www.nhs.uk/conditions/hormone-replacement-therapy-hrt/. Accessed June 2025.
3. NICE. Menopause: diagnosis and management. NG23. Updated December 2019. Available at: https://www.nice.org.uk/guidance/ng23. Accessed June 2025.
4. British National Formulary (BNF). Estradiol — transdermal gel preparations. Available at: https://bnf.nice.org.uk. Accessed June 2025.
5. MHRA. Hormone-replacement therapy: updated advice. Drug Safety Update vol 12 issue 11, June 2019. Available at: https://www.gov.uk/drug-safety-update. Accessed June 2025.
6. Vinogradova Y et al. Use of hormone replacement therapy and risk of venous thromboembolism. BMJ 2019; 364:k4810.
7. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk. Lancet 2019; 394(10204):1159–1168.
8. British Menopause Society. Recommendations on transdermal HRT. Available at: https://thebms.org.uk. Accessed June 2025.